423 related articles for article (PubMed ID: 27530808)
21. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.
Dong-Si T; Gheuens S; Gangadharan A; Wenten M; Philip J; McIninch J; Datta S; Richert N; Bozic C; Bloomgren G; Richman S; Weber T; Clifford DB
J Neurovirol; 2015 Dec; 21(6):637-44. PubMed ID: 25771865
[TBL] [Abstract][Full Text] [Related]
22. Concomitant granule cell neuronopathy in patients with natalizumab-associated PML.
Wijburg MT; Siepman D; van Eijk JJ; Killestein J; Wattjes MP
J Neurol; 2016 Apr; 263(4):649-56. PubMed ID: 26810721
[TBL] [Abstract][Full Text] [Related]
23. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
Vennegoor A; Rispens T; Van Oosten BW; Wattjes MP; Wondergem MJ; Teunissen CE; Van der Kleij D; Uitdehaag BM; Polman CH; Killestein J
Mult Scler; 2015 Apr; 21(4):481-4. PubMed ID: 25078275
[TBL] [Abstract][Full Text] [Related]
24. Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort.
Wijburg MT; Warnke C; Barkhof F; Uitdehaag BMJ; Killestein J; Wattjes MP
J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):44-46. PubMed ID: 30100552
[TBL] [Abstract][Full Text] [Related]
25. Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks.
Maloney E; Molloy A; Al Hussona M; O'Donnell L; Killeen R; McGuigan C
J Neurol; 2017 Feb; 264(2):401-403. PubMed ID: 28039520
[No Abstract] [Full Text] [Related]
26. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
[TBL] [Abstract][Full Text] [Related]
27. Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question.
De Mercanti SF; Gned D; Matta M; Iudicello M; Franchin E; Clerico M
J Investig Med High Impact Case Rep; 2020; 8():2324709620939802. PubMed ID: 32646245
[TBL] [Abstract][Full Text] [Related]
28. Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy.
Hoepner R; Kolb EM; Dahlhaus S; Hellwig K; Adams O; Kleiter I; Salmen A; Schneider R; Lukas C; Chan A; Berger JR; Gold R
Mult Scler; 2017 May; 23(6):830-835. PubMed ID: 27600113
[TBL] [Abstract][Full Text] [Related]
29. No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.
Ryerson LZ; Naismith RT; Krupp LB; Charvet LE; Liao S; Fisher E; de Moor C; Williams JR; Campbell N
Mult Scler Relat Disord; 2022 Feb; 58():103480. PubMed ID: 35051898
[TBL] [Abstract][Full Text] [Related]
30. CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study.
Häusler D; Akgün K; Stork L; Lassmann H; Ziemssen T; Brück W; Metz I
Brain Pathol; 2021 Nov; 31(6):e12969. PubMed ID: 33955606
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI.
Wattjes MP; Barkhof F
Curr Opin Neurol; 2014 Jun; 27(3):260-70. PubMed ID: 24739400
[TBL] [Abstract][Full Text] [Related]
32. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
Lanza Cariccio V; Bramanti P; Mazzon E
Mult Scler Relat Disord; 2018 Feb; 20():93-99. PubMed ID: 29353737
[TBL] [Abstract][Full Text] [Related]
33. Application of "Mentzer's PML case definition" to natalizumab-treated patients in the setting of strict MRI-based pharmacovigilance.
Wijburg MT; Warnke C; Killestein J; Wattjes MP
J Neurol; 2020 Sep; 267(9):2599-2602. PubMed ID: 32385682
[TBL] [Abstract][Full Text] [Related]
34. Cortical hypointensity in T2-weighted gradient-echo sequences in patients with progressive multifocal leukoencephalopathy.
López Sala P; Alberdi Aldasoro N; Zelaya Huerta MV; Bacaicoa Saralegui MC; Cabada Giadás T
Radiologia (Engl Ed); 2020; 62(1):59-66. PubMed ID: 31375267
[TBL] [Abstract][Full Text] [Related]
35. Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML.
Alleg M; Solis M; Baloglu S; Cotton F; Kerschen P; Bourre B; Ahle G; Pruvo JP; Leclerc X; Vermersch P; Papeix C; Maillart É; Houillier C; Chabrot CM; Claise B; Malak S; Martin-Blondel G; Bonneville F; Caulier A; Marolleau JP; Bonnefoy JT; Agape P; Kennel C; Roussel X; Chauchet A; De Seze J; Fafi-Kremer S; Kremer S
Eur Radiol; 2021 May; 31(5):2944-2955. PubMed ID: 33155106
[TBL] [Abstract][Full Text] [Related]
36. Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry.
Prosperini L; de Rossi N; Scarpazza C; Moiola L; Cosottini M; Gerevini S; Capra R;
PLoS One; 2016; 11(12):e0168376. PubMed ID: 27997580
[TBL] [Abstract][Full Text] [Related]
37. Quantitative electroencephalography supports diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.
Classen G; Classen C; Bernasconi C; Brandt C; Gold R; Chan A; Hoepner R
J Neurovirol; 2019 Feb; 25(1):133-136. PubMed ID: 30414049
[TBL] [Abstract][Full Text] [Related]
38. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.
van Kempen ZL; Leurs CE; Vennegoor A; Wattjes MP; Rispens T; Uitdehaag BM; Killestein J
Mult Scler; 2017 Jun; 23(7):995-999. PubMed ID: 28112019
[TBL] [Abstract][Full Text] [Related]
39. JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.
Basnyat P; Virtanen E; Elovaara I; Hagman S; Auvinen E
J Neurovirol; 2017 Oct; 23(5):734-741. PubMed ID: 28831768
[TBL] [Abstract][Full Text] [Related]
40. [Natalizumab can induce progressive multifocal leucoencephalopathy].
Theódórsdóttir A; Blaabjerg M; Falah M
Ugeskr Laeger; 2014 Aug; 176(35):. PubMed ID: 25293706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
